Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. developed full-length multispecific antibodies and antibody drug conjugates for oncology before its completed tender-offer transaction with Genmab. Company news centered on the Multiclonics® platform, Biclonics®, Triclonics® and ADClonics®, and the lead bispecific antibody petosemtamab, an EGFR x LGR5 program studied in solid tumors including head and neck cancer and metastatic colorectal cancer.
Recurring updates include petosemtamab clinical data, conference presentations, collaboration and license activity such as the ENHANZE® subcutaneous-delivery agreement with Halozyme, and corporate-status developments tied to the Genmab transaction. Other recurring items include investor conference appearances, material agreements, governance matters, capital-structure disclosures, and operating or financial results when reported.
Merus N.V. announced financial results for Q1 2024 and provided updates on its innovative oncology treatments. Petosemtamab in combination with pembrolizumab showed promising results in HNSCC, Zeno BLA accepted for priority review by FDA for NRG1+ NSCLC and PDAC. Cash runway expected into 2027. Collaboration with Incyte, Eli Lilly, and Gilead progressing well. Financially, a decrease in collaboration revenue but an increase in R&D and G&A expenses reported.
Merus N.V. announced that the U.S. FDA has accepted a priority review for the Biologics License Application of the bispecific antibody zenocutuzumab (Zeno) for NRG1+ NSCLC and PDAC. If approved, Zeno will be the first targeted therapy for NRG1+ cancer, offering a potential breakthrough in treatment options for patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.